Lipid Matrix Dosage Forms With Curing for Stable API Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Solid and semisolid lipid matrices in pharmaceutical compositions exhibit unstable dissolution release profiles over time, leading to potential under-dosing or over-dosing of active pharmaceutical ingredients due to changes in lipid crystal form, which existing stabilization methods have failed to address effectively.
Innovation Solution
Incorporation of a surfactant with an HLB value of less than 10 into a dosage form comprising a solid or semisolid lipid matrix, combined with curing, stabilizes the release profile of the active pharmaceutical ingredient.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If solid or semisolid lipid matrices are used in pharmaceutical compositions, then the active pharmaceutical ingredient can be delivered in a controlled release manner, but the release profile becomes unstable over time due to changes in lipid crystal form
Solution Approach 1:
The patent applies parameter changes by curing the lipid matrix through controlled oxidation, which fundamentally alters the chemical and physical parameters of the lipid structure. This curing process transforms the unstable, changing crystal forms into a stabilized, cross-linked network that maintains consistent release characteristics over time, directly resolving the contradiction between controlled release and release stability.
Solution Approach 2:
The patent creates a composite material system by combining the active pharmaceutical ingredient with a cured lipid matrix that contains oxidized lipid species. This composite structure integrates the release functionality of the lipid matrix with the stabilizing effect of oxidation, producing a material that maintains both controlled release and temporal stability, thereby resolving the contradiction between duration of action and reliability.
2Duration of action of moving object
If curing is applied to stabilize the lipid matrix, then the release profile stability improves, but the manufacturing process complexity increases
Solution Approach 1:
The patent applies preliminary action by incorporating antioxidants or pro-oxidants during the initial formulation stage, which then undergo oxidation during storage or under specific conditions to achieve curing. This allows the stabilizing effect to be built into the material over time rather than requiring complex post-manufacturing treatment processes, thus improving release stability without significantly increasing manufacturing complexity.
Solution Approach 2:
The patent employs self-service by allowing the lipid matrix to cure through spontaneous oxidation during storage or under mild conditions, rather than requiring complex external curing equipment or processes. The material essentially cures itself through its inherent chemical properties, achieving stabilization without adding significant manufacturing complexity or requiring specialized equipment.
3Duration of action of moving object
If surfactants with HLB values greater than 10 are used, then the release profile shows some improvement, but the stabilization effect is insufficient to maintain consistency over extended periods
Solution Approach 1:
The patent applies parameter changes by shifting from using surfactants with HLB values greater than 10 to using surfactants with HLB values less than or equal to 10, and/or by changing the lipid matrix from uncured to cured through oxidation. This parameter change in surfactant selection and matrix state fundamentally improves long-term release consistency by creating a more stable interface and network structure that maintains release characteristics over extended periods.
Solution Approach 2:
The patent creates a composite material system that combines surfactants with HLB values less than or equal to 10 with a cured lipid matrix. This composite approach synergistically improves long-term release consistency by integrating the surfactant's ability to stabilize interfaces with the curing process's creation of a rigid, stable network, thereby achieving superior long-term reliability compared to using high HLB surfactants alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method ensures a stable release profile of the active pharmaceutical ingredient over time, maintaining similarity factors (f2) comparable to the initial profile after accelerated stability studies, reducing the need for frequent dosing and minimizing excipient use.
Implementation Method 1
a surfactant with an HLB value of less than 10
Implementation Method 2
curing the dosage form
Data Source
AI summary
Disclosed herein are dosage forms comprise a solid or a semisolid lipid with immediate release properties and/or with extended release properties. The dosage forms disclosed herein may have their active pharmaceutical ingredient's (API's) release profile stabilized via curing and/or via the addition of a surfactant with an HLB value of less than 10.